APO Research
Talk to an analyst

APO RESEARCH · REPORT

Chronic Refractory Cough (CRC) Treatment

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Chronic Refractory Cough (CRC) Treatment Market Analysis and Forecast 2026-2032

19 December 2025197 pages

Choose your research edition.

Industry ResearchChronic Refractory Cough (CRC) Treatment Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal Chronic Refractory Cough (CRC) Treatment Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Chronic Refractory Cough (CRC) Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chronic Refractory Cough (CRC) Treatment Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Chronic Refractory Cough (CRC) Treatment Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Chronic Refractory Cough (CRC) Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Chronic Refractory Cough (CRC) Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Chronic Refractory Cough (CRC) Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Chronic Refractory Cough (CRC) Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Chronic Refractory Cough (CRC) Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Chronic Refractory Cough (CRC) Treatment include Shionogi, Merck, Respivant Sciences, Nerre Therapeutics, Bellus Health and Attenua, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Chronic Refractory Cough (CRC) Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Chronic Refractory Cough (CRC) Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Chronic Refractory Cough (CRC) Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Chronic Refractory Cough (CRC) Treatment revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Chronic Refractory Cough (CRC) Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Chronic Refractory Cough (CRC) Treatment revenue, projected growth trends, production technology, application and end-user industry.

Chronic Refractory Cough (CRC) Treatment Segment by Company

Shionogi

Merck

Respivant Sciences

Nerre Therapeutics

Bellus Health

Attenua

Chronic Refractory Cough (CRC) Treatment Segment by Type

Speech Therapy

Physiotherapy

Chronic Refractory Cough (CRC) Treatment Segment by Application

Hospital

Clinic

Others

Chronic Refractory Cough (CRC) Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chronic Refractory Cough (CRC) Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chronic Refractory Cough (CRC) Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chronic Refractory Cough (CRC) Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Chronic Refractory Cough (CRC) Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Chronic Refractory Cough (CRC) Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Chronic Refractory Cough (CRC) Treatment revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Chronic Refractory Cough (CRC) Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Speech Therapy Major Player Table 3. Physiotherapy Major Player Table 4. Global Chronic Refractory Cough (CRC) Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Player Table 6. Clinic Major Player Table 7. Others Major Player Table 8. Chronic Refractory Cough (CRC) Treatment Industry Trends Table 9. Chronic Refractory Cough (CRC) Treatment Industry Drivers Table 10. Chronic Refractory Cough (CRC) Treatment Industry Opportunities and Challenges Table 11. Chronic Refractory Cough (CRC) Treatment Industry Restraints Table 12. Global Chronic Refractory Cough (CRC) Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Chronic Refractory Cough (CRC) Treatment Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Chronic Refractory Cough (CRC) Treatment Market Share by Region (2021-2026) Table 15. Global Chronic Refractory Cough (CRC) Treatment Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Chronic Refractory Cough (CRC) Treatment Market Share by Region (2027-2032) Table 17. Global Chronic Refractory Cough (CRC) Treatment Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Chronic Refractory Cough (CRC) Treatment Revenue Market Share by Players (2021-2026) Table 19. Global Chronic Refractory Cough (CRC) Treatment Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Chronic Refractory Cough (CRC) Treatment Key Players Headquarters & Area Served Table 21. Global Chronic Refractory Cough (CRC) Treatment Players, Product Type & Application Table 22. Global Chronic Refractory Cough (CRC) Treatment Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Chronic Refractory Cough (CRC) Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Chronic Refractory Cough (CRC) Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Chronic Refractory Cough (CRC) Treatment Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Chronic Refractory Cough (CRC) Treatment Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Chronic Refractory Cough (CRC) Treatment Revenue Market Share by Type (2021-2026) Table 29. Global Chronic Refractory Cough (CRC) Treatment Revenue Market Share by Type (2027-2032) Table 30. Global Chronic Refractory Cough (CRC) Treatment Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Chronic Refractory Cough (CRC) Treatment Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Chronic Refractory Cough (CRC) Treatment Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Chronic Refractory Cough (CRC) Treatment Revenue Market Share by Application (2021-2026) Table 34. Global Chronic Refractory Cough (CRC) Treatment Revenue Market Share by Application (2027-2032) Table 35. Shionogi Company Information Table 36. Shionogi Business Overview Table 37. Shionogi Chronic Refractory Cough (CRC) Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Shionogi Chronic Refractory Cough (CRC) Treatment Product Portfolio Table 39. Shionogi Recent Development Table 40. Merck Company Information Table 41. Merck Business Overview Table 42. Merck Chronic Refractory Cough (CRC) Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Merck Chronic Refractory Cough (CRC) Treatment Product Portfolio Table 44. Merck Recent Development Table 45. Respivant Sciences Company Information Table 46. Respivant Sciences Business Overview Table 47. Respivant Sciences Chronic Refractory Cough (CRC) Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Respivant Sciences Chronic Refractory Cough (CRC) Treatment Product Portfolio Table 49. Respivant Sciences Recent Development Table 50. Nerre Therapeutics Company Information Table 51. Nerre Therapeutics Business Overview Table 52. Nerre Therapeutics Chronic Refractory Cough (CRC) Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Nerre Therapeutics Chronic Refractory Cough (CRC) Treatment Product Portfolio Table 54. Nerre Therapeutics Recent Development Table 55. Bellus Health Company Information Table 56. Bellus Health Business Overview Table 57. Bellus Health Chronic Refractory Cough (CRC) Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Bellus Health Chronic Refractory Cough (CRC) Treatment Product Portfolio Table 59. Bellus Health Recent Development Table 60. Attenua Company Information Table 61. Attenua Business Overview Table 62. Attenua Chronic Refractory Cough (CRC) Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Attenua Chronic Refractory Cough (CRC) Treatment Product Portfolio Table 64. Attenua Recent Development Table 65. North America Chronic Refractory Cough (CRC) Treatment Revenue by Type (2021-2026) & (US$ Million) Table 66. North America Chronic Refractory Cough (CRC) Treatment Revenue by Type (2027-2032) & (US$ Million) Table 67. North America Chronic Refractory Cough (CRC) Treatment Revenue by Application (2021-2026) & (US$ Million) Table 68. North America Chronic Refractory Cough (CRC) Treatment Revenue by Application (2027-2032) & (US$ Million) Table 69. North America Chronic Refractory Cough (CRC) Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 70. North America Chronic Refractory Cough (CRC) Treatment Revenue by Country (2021-2026) & (US$ Million) Table 71. North America Chronic Refractory Cough (CRC) Treatment Revenue by Country (US$ Million) & (2027-2032) Table 72. Europe Chronic Refractory Cough (CRC) Treatment Revenue by Type (2021-2026) & (US$ Million) Table 73. Europe Chronic Refractory Cough (CRC) Treatment Revenue by Type (2027-2032) & (US$ Million) Table 74. Europe Chronic Refractory Cough (CRC) Treatment Revenue by Application (2021-2026) & (US$ Million) Table 75. Europe Chronic Refractory Cough (CRC) Treatment Revenue by Application (2027-2032) & (US$ Million) Table 76. Europe Chronic Refractory Cough (CRC) Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 77. Europe Chronic Refractory Cough (CRC) Treatment Revenue by Country (2021-2026) & (US$ Million) Table 78. Europe Chronic Refractory Cough (CRC) Treatment Revenue by Country (US$ Million) & (2027-2032) Table 79. China Chronic Refractory Cough (CRC) Treatment Revenue by Type (2021-2026) & (US$ Million) Table 80. China Chronic Refractory Cough (CRC) Treatment Revenue by Type (2027-2032) & (US$ Million) Table 81. China Chronic Refractory Cough (CRC) Treatment Revenue by Application (2021-2026) & (US$ Million) Table 82. China Chronic Refractory Cough (CRC) Treatment Revenue by Application (2027-2032) & (US$ Million) Table 83. Asia Chronic Refractory Cough (CRC) Treatment Revenue by Type (2021-2026) & (US$ Million) Table 84. Asia Chronic Refractory Cough (CRC) Treatment Revenue by Type (2027-2032) & (US$ Million) Table 85. Asia Chronic Refractory Cough (CRC) Treatment Revenue by Application (2021-2026) & (US$ Million) Table 86. Asia Chronic Refractory Cough (CRC) Treatment Revenue by Application (2027-2032) & (US$ Million) Table 87. Asia Chronic Refractory Cough (CRC) Treatment Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 88. Asia Chronic Refractory Cough (CRC) Treatment Revenue by Region (US$ Million) & (2021-2026) Table 89. Asia Chronic Refractory Cough (CRC) Treatment Revenue by Region (US$ Million) & (2027-2032) Table 90. SAMEA Chronic Refractory Cough (CRC) Treatment Revenue by Type (2021-2026) & (US$ Million) Table 91. SAMEA Chronic Refractory Cough (CRC) Treatment Revenue by Type (2027-2032) & (US$ Million) Table 92. SAMEA Chronic Refractory Cough (CRC) Treatment Revenue by Application (2021-2026) & (US$ Million) Table 93. SAMEA Chronic Refractory Cough (CRC) Treatment Revenue by Application (2027-2032) & (US$ Million) Table 94. SAMEA Chronic Refractory Cough (CRC) Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 95. SAMEA Chronic Refractory Cough (CRC) Treatment Revenue by Country (2021-2026) & (US$ Million) Table 96. SAMEA Chronic Refractory Cough (CRC) Treatment Revenue by Country (US$ Million) & (2027-2032) Table 97. Research Programs/Design for This Report Table 98. Authors List of This Report Table 99. Secondary Sources Table 100. Primary Sources List of Figures Figure 1. Chronic Refractory Cough (CRC) Treatment Image Figure 2. Global Chronic Refractory Cough (CRC) Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Chronic Refractory Cough (CRC) Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. Speech Therapy Image Figure 5. Physiotherapy Image Figure 6. Global Chronic Refractory Cough (CRC) Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Chronic Refractory Cough (CRC) Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Clinic Image Figure 10. Others Image Figure 11. Global Chronic Refractory Cough (CRC) Treatment Market Size (US$ Million) & (2021-2032) Figure 12. Global Chronic Refractory Cough (CRC) Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Chronic Refractory Cough (CRC) Treatment Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Chronic Refractory Cough (CRC) Treatment Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Chronic Refractory Cough (CRC) Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Chronic Refractory Cough (CRC) Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Chronic Refractory Cough (CRC) Treatment Revenue Market Share by Type (2021-2032) Figure 19. Global Chronic Refractory Cough (CRC) Treatment Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Chronic Refractory Cough (CRC) Treatment Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Chronic Refractory Cough (CRC) Treatment Revenue Market Share by Application (2021-2032) Figure 22. North America Chronic Refractory Cough (CRC) Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Chronic Refractory Cough (CRC) Treatment Revenue Share by Type (2021-2032) Figure 24. North America Chronic Refractory Cough (CRC) Treatment Revenue Share by Application (2021-2032) Figure 25. North America Chronic Refractory Cough (CRC) Treatment Revenue Share by Country (2021-2032) Figure 26. United States Chronic Refractory Cough (CRC) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Chronic Refractory Cough (CRC) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Chronic Refractory Cough (CRC) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Chronic Refractory Cough (CRC) Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Chronic Refractory Cough (CRC) Treatment Revenue Share by Type (2021-2032) Figure 31. Europe Chronic Refractory Cough (CRC) Treatment Revenue Share by Application (2021-2032) Figure 32. Europe Chronic Refractory Cough (CRC) Treatment Revenue Share by Country (2021-2032) Figure 33. Germany Chronic Refractory Cough (CRC) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Chronic Refractory Cough (CRC) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Chronic Refractory Cough (CRC) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Chronic Refractory Cough (CRC) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Chronic Refractory Cough (CRC) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Chronic Refractory Cough (CRC) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Chronic Refractory Cough (CRC) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Chronic Refractory Cough (CRC) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Chronic Refractory Cough (CRC) Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Chronic Refractory Cough (CRC) Treatment Revenue Share by Type (2021-2032) Figure 43. China Chronic Refractory Cough (CRC) Treatment Revenue Share by Application (2021-2032) Figure 44. Asia Chronic Refractory Cough (CRC) Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Chronic Refractory Cough (CRC) Treatment Revenue Share by Type (2021-2032) Figure 46. Asia Chronic Refractory Cough (CRC) Treatment Revenue Share by Application (2021-2032) Figure 47. Asia Chronic Refractory Cough (CRC) Treatment Revenue Share by Region (2021-2032) Figure 48. Japan Chronic Refractory Cough (CRC) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Chronic Refractory Cough (CRC) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Chronic Refractory Cough (CRC) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Chronic Refractory Cough (CRC) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Chronic Refractory Cough (CRC) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Chronic Refractory Cough (CRC) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Chronic Refractory Cough (CRC) Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Chronic Refractory Cough (CRC) Treatment Revenue Share by Type (2021-2032) Figure 56. SAMEA Chronic Refractory Cough (CRC) Treatment Revenue Share by Application (2021-2032) Figure 57. SAMEA Chronic Refractory Cough (CRC) Treatment Revenue Share by Country (2021-2032) Figure 58. Brazil Chronic Refractory Cough (CRC) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Chronic Refractory Cough (CRC) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Chronic Refractory Cough (CRC) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Chronic Refractory Cough (CRC) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Chronic Refractory Cough (CRC) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Chronic Refractory Cough (CRC) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Chronic Refractory Cough (CRC) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Chronic Refractory Cough (CRC) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Chronic Refractory Cough (CRC) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Chronic Refractory Cough (CRC) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Chronic Refractory Cough (CRC) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Speech Therapy
  • Physiotherapy
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Shionogi
  • Merck
  • Respivant Sciences
  • Nerre Therapeutics
  • Bellus Health
  • Attenua

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Chronic Refractory Cough (CRC) Treatment Market by Type
  3. 1.2.1 Global Chronic Refractory Cough (CRC) Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Speech Therapy
  5. 1.2.3 Physiotherapy
  6. 1.3 Chronic Refractory Cough (CRC) Treatment Market by Application
  7. 1.3.1 Global Chronic Refractory Cough (CRC) Treatment Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Clinic
  10. 1.3.4 Others
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Chronic Refractory Cough (CRC) Treatment Market Dynamics
  1. 2.1 Chronic Refractory Cough (CRC) Treatment Industry Trends
  2. 2.2 Chronic Refractory Cough (CRC) Treatment Industry Drivers
  3. 2.3 Chronic Refractory Cough (CRC) Treatment Industry Opportunities and Challenges
  4. 2.4 Chronic Refractory Cough (CRC) Treatment Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Chronic Refractory Cough (CRC) Treatment Market Perspective (2021-2032)
  2. 3.2 Global Chronic Refractory Cough (CRC) Treatment Growth Trends by Region
  3. 3.2.1 Global Chronic Refractory Cough (CRC) Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Chronic Refractory Cough (CRC) Treatment Market Size by Region (2021-2026)
  5. 3.2.3 Global Chronic Refractory Cough (CRC) Treatment Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Chronic Refractory Cough (CRC) Treatment Revenue by Players
  2. 4.1.1 Global Chronic Refractory Cough (CRC) Treatment Revenue by Players (2021-2026)
  3. 4.1.2 Global Chronic Refractory Cough (CRC) Treatment Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Chronic Refractory Cough (CRC) Treatment Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Chronic Refractory Cough (CRC) Treatment Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Chronic Refractory Cough (CRC) Treatment Key Players Headquarters & Area Served
  7. 4.4 Global Chronic Refractory Cough (CRC) Treatment Players, Product Type & Application
  8. 4.5 Global Chronic Refractory Cough (CRC) Treatment Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Chronic Refractory Cough (CRC) Treatment Market CR5 and HHI
  11. 4.6.3 2025 Chronic Refractory Cough (CRC) Treatment Tier 1, Tier 2, and Tier 3
5 Chronic Refractory Cough (CRC) Treatment Market Size by Type
  1. 5.1 Global Chronic Refractory Cough (CRC) Treatment Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Chronic Refractory Cough (CRC) Treatment Revenue by Type (2021-2032)
  3. 5.3 Global Chronic Refractory Cough (CRC) Treatment Revenue Market Share by Type (2021-2032)
6 Chronic Refractory Cough (CRC) Treatment Market Size by Application
  1. 6.1 Global Chronic Refractory Cough (CRC) Treatment Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Chronic Refractory Cough (CRC) Treatment Revenue by Application (2021-2032)
  3. 6.3 Global Chronic Refractory Cough (CRC) Treatment Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Shionogi
  2. 7.1.1 Shionogi Company Information
  3. 7.1.2 Shionogi Business Overview
  4. 7.1.3 Shionogi Chronic Refractory Cough (CRC) Treatment Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Shionogi Chronic Refractory Cough (CRC) Treatment Product Portfolio
  6. 7.1.5 Shionogi Recent Developments
  7. 7.2 Merck
  8. 7.2.1 Merck Company Information
  9. 7.2.2 Merck Business Overview
  10. 7.2.3 Merck Chronic Refractory Cough (CRC) Treatment Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Merck Chronic Refractory Cough (CRC) Treatment Product Portfolio
  12. 7.2.5 Merck Recent Developments
  13. 7.3 Respivant Sciences
  14. 7.3.1 Respivant Sciences Company Information
  15. 7.3.2 Respivant Sciences Business Overview
  16. 7.3.3 Respivant Sciences Chronic Refractory Cough (CRC) Treatment Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Respivant Sciences Chronic Refractory Cough (CRC) Treatment Product Portfolio
  18. 7.3.5 Respivant Sciences Recent Developments
  19. 7.4 Nerre Therapeutics
  20. 7.4.1 Nerre Therapeutics Company Information
  21. 7.4.2 Nerre Therapeutics Business Overview
  22. 7.4.3 Nerre Therapeutics Chronic Refractory Cough (CRC) Treatment Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Nerre Therapeutics Chronic Refractory Cough (CRC) Treatment Product Portfolio
  24. 7.4.5 Nerre Therapeutics Recent Developments
  25. 7.5 Bellus Health
  26. 7.5.1 Bellus Health Company Information
  27. 7.5.2 Bellus Health Business Overview
  28. 7.5.3 Bellus Health Chronic Refractory Cough (CRC) Treatment Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Bellus Health Chronic Refractory Cough (CRC) Treatment Product Portfolio
  30. 7.5.5 Bellus Health Recent Developments
  31. 7.6 Attenua
  32. 7.6.1 Attenua Company Information
  33. 7.6.2 Attenua Business Overview
  34. 7.6.3 Attenua Chronic Refractory Cough (CRC) Treatment Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Attenua Chronic Refractory Cough (CRC) Treatment Product Portfolio
  36. 7.6.5 Attenua Recent Developments
8 North America
  1. 8.1 North America Chronic Refractory Cough (CRC) Treatment Revenue (2021-2032)
  2. 8.2 North America Chronic Refractory Cough (CRC) Treatment Revenue by Type (2021-2032)
  3. 8.2.1 North America Chronic Refractory Cough (CRC) Treatment Revenue by Type (2021-2026)
  4. 8.2.2 North America Chronic Refractory Cough (CRC) Treatment Revenue by Type (2027-2032)
  5. 8.3 North America Chronic Refractory Cough (CRC) Treatment Revenue Share by Type (2021-2032)
  6. 8.4 North America Chronic Refractory Cough (CRC) Treatment Revenue by Application (2021-2032)
  7. 8.4.1 North America Chronic Refractory Cough (CRC) Treatment Revenue by Application (2021-2026)
  8. 8.4.2 North America Chronic Refractory Cough (CRC) Treatment Revenue by Application (2027-2032)
  9. 8.5 North America Chronic Refractory Cough (CRC) Treatment Revenue Share by Application (2021-2032)
  10. 8.6 North America Chronic Refractory Cough (CRC) Treatment Revenue by Country
  11. 8.6.1 North America Chronic Refractory Cough (CRC) Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Chronic Refractory Cough (CRC) Treatment Revenue by Country (2021-2026)
  13. 8.6.3 North America Chronic Refractory Cough (CRC) Treatment Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Chronic Refractory Cough (CRC) Treatment Revenue (2021-2032)
  2. 9.2 Europe Chronic Refractory Cough (CRC) Treatment Revenue by Type (2021-2032)
  3. 9.2.1 Europe Chronic Refractory Cough (CRC) Treatment Revenue by Type (2021-2026)
  4. 9.2.2 Europe Chronic Refractory Cough (CRC) Treatment Revenue by Type (2027-2032)
  5. 9.3 Europe Chronic Refractory Cough (CRC) Treatment Revenue Share by Type (2021-2032)
  6. 9.4 Europe Chronic Refractory Cough (CRC) Treatment Revenue by Application (2021-2032)
  7. 9.4.1 Europe Chronic Refractory Cough (CRC) Treatment Revenue by Application (2021-2026)
  8. 9.4.2 Europe Chronic Refractory Cough (CRC) Treatment Revenue by Application (2027-2032)
  9. 9.5 Europe Chronic Refractory Cough (CRC) Treatment Revenue Share by Application (2021-2032)
  10. 9.6 Europe Chronic Refractory Cough (CRC) Treatment Revenue by Country
  11. 9.6.1 Europe Chronic Refractory Cough (CRC) Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Chronic Refractory Cough (CRC) Treatment Revenue by Country (2021-2026)
  13. 9.6.3 Europe Chronic Refractory Cough (CRC) Treatment Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Chronic Refractory Cough (CRC) Treatment Revenue (2021-2032)
  2. 10.2 China Chronic Refractory Cough (CRC) Treatment Revenue by Type (2021-2032)
  3. 10.2.1 China Chronic Refractory Cough (CRC) Treatment Revenue by Type (2021-2026)
  4. 10.2.2 China Chronic Refractory Cough (CRC) Treatment Revenue by Type (2027-2032)
  5. 10.3 China Chronic Refractory Cough (CRC) Treatment Revenue Share by Type (2021-2032)
  6. 10.4 China Chronic Refractory Cough (CRC) Treatment Revenue by Application (2021-2032)
  7. 10.4.1 China Chronic Refractory Cough (CRC) Treatment Revenue by Application (2021-2026)
  8. 10.4.2 China Chronic Refractory Cough (CRC) Treatment Revenue by Application (2027-2032)
  9. 10.5 China Chronic Refractory Cough (CRC) Treatment Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Chronic Refractory Cough (CRC) Treatment Revenue (2021-2032)
  2. 11.2 Asia Chronic Refractory Cough (CRC) Treatment Revenue by Type (2021-2032)
  3. 11.2.1 Asia Chronic Refractory Cough (CRC) Treatment Revenue by Type (2021-2026)
  4. 11.2.2 Asia Chronic Refractory Cough (CRC) Treatment Revenue by Type (2027-2032)
  5. 11.3 Asia Chronic Refractory Cough (CRC) Treatment Revenue Share by Type (2021-2032)
  6. 11.4 Asia Chronic Refractory Cough (CRC) Treatment Revenue by Application (2021-2032)
  7. 11.4.1 Asia Chronic Refractory Cough (CRC) Treatment Revenue by Application (2021-2026)
  8. 11.4.2 Asia Chronic Refractory Cough (CRC) Treatment Revenue by Application (2027-2032)
  9. 11.5 Asia Chronic Refractory Cough (CRC) Treatment Revenue Share by Application (2021-2032)
  10. 11.6 Asia Chronic Refractory Cough (CRC) Treatment Revenue by Country
  11. 11.6.1 Asia Chronic Refractory Cough (CRC) Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Chronic Refractory Cough (CRC) Treatment Revenue by Country (2021-2026)
  13. 11.6.3 Asia Chronic Refractory Cough (CRC) Treatment Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Chronic Refractory Cough (CRC) Treatment Revenue (2021-2032)
  2. 12.2 SAMEA Chronic Refractory Cough (CRC) Treatment Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Chronic Refractory Cough (CRC) Treatment Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Chronic Refractory Cough (CRC) Treatment Revenue by Type (2027-2032)
  5. 12.3 SAMEA Chronic Refractory Cough (CRC) Treatment Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Chronic Refractory Cough (CRC) Treatment Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Chronic Refractory Cough (CRC) Treatment Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Chronic Refractory Cough (CRC) Treatment Revenue by Application (2027-2032)
  9. 12.5 SAMEA Chronic Refractory Cough (CRC) Treatment Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Chronic Refractory Cough (CRC) Treatment Revenue by Country
  11. 12.6.1 SAMEA Chronic Refractory Cough (CRC) Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Chronic Refractory Cough (CRC) Treatment Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Chronic Refractory Cough (CRC) Treatment Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst